LSAK
Lesaka Technologies, Inc.
LSAK trails on the overall score without a compensating advantage in the available component scores.
NVDA
NVIDIA Corporation
NVDA has the edge over LSAK overall, supported by stronger valuation and stronger modeled upside.
LSAK Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Healthy | |
| Stable | |
| Stable |
LSAK's revenue and profitability are currently healthy, and its cash flow and balance sheet are stable.
NVDA Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Strong | |
| Strong | |
| Strong |
NVDA's revenue, profitability, cash flow and balance sheet are all currently strong.
LSAK PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 111x | $3.32 | — |
| Cheap | 125x | $3.75 | +13% |
| Fair | 140x | $4.19 | +26% |
| Expensive | 146x | $4.39 | +32% |
Historical ranges are pointers, not guarantees.
LSAK's PE is 111x, but its earnings don't support one, so it isn't a reliable read right now.
NVDA PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $166 | — |
| Current | 21x | $166 | — |
| Cheap | 44x | $345 | +108% |
| Fair | 65x | $511 | +207% |
| Expensive | 93x | $734 | +342% |
Historical ranges are pointers, not guarantees.
NVDA's PE is in its cheap range at 21x. If earnings grow as analysts expect, today's price would be 12x next year's earnings.
LSAK Forward outlook
There aren't enough analyst estimates for LSAK to show an outlook.
NVDA Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Weakening | |
| Broad | |
| Moderate |
Analysts expect strong earnings and revenue growth for NVDA, but weaker profitability.
LSAK Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | $0.03 | +$1.15 |
| Q2 2026 | $0.03 | +$1.17 |
| Q1 2026 | -$0.40 | +$0.42 |
| Q4 2025 | -$0.68 | -$0.07 |
| Q3 2025 | -$1.12 | -$0.87 |
| Q2 2025 | -$1.14 | -$0.87 |
| Q3 2022 | -$0.69 | -$0.30 |
| Q2 2022 | -$0.75 | -$0.08 |
LSAK has returned to profit: it earned $0.03 per share over the past year, after losing money the year before.
NVDA Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $13.77 | +74% |
| Q3 2026 | $7.91 | +125% |
| Q2 2026 | $6.53 | +111% |
| Q1 2026 | $4.90 | +67% |
| Q4 2025 | $4.03 | +59% |
| Q3 2025 | $3.51 | +65% |
| Q2 2025 | $3.10 | +81% |
| Q1 2025 | $2.94 | +147% |
| Q4 2024 | $2.54 | +234% |
NVDA has the edge over LSAK on earnings, with more consistent year-over-year improvement.
LSAK Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $184.6M | +7.7% |
| Q2 2026 | $188.3M | +12% |
| Q1 2026 | $183.1M | +13% |
| Q4 2025 | $178.7M | +1.4% |
| Q3 2025 | $171.4M | +12% |
| Q2 2025 | $168.5M | +15% |
| Q1 2025 | $161.5M | +17% |
| Q4 2024 | $176.2M | +22% |
LSAK's revenue has grown year over year for 19 quarters in a row: $185M last quarter, up 7.7% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -0.6% | -0.8 points |
| Q2 2026 | 3.4% | +20 points |
| Q1 2026 | 2.2% | +1.9 points |
| Q4 2025 | 1.2% | +0.8 points |
| Q3 2025 | 0.2% | +0.3 points |
| Q2 2025 | -17% | -17 points |
| Q1 2025 | 0.3% | -0.2 points |
| Q4 2024 | 0.4% | -1.1 points |
LSAK's operating margin was −0.6% last quarter, down 0.8 points from the same quarter a year ago.
NVDA Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $96.2B | +106% |
| Q2 2026 | $81.6B | +85% |
| Q1 2026 | $68.1B | +73% |
| Q4 2025 | $57B | +62% |
| Q3 2025 | $46.7B | +56% |
| Q2 2025 | $44.1B | +69% |
| Q1 2025 | $39.3B | +78% |
| Q4 2024 | $35.1B | +94% |
NVDA has the edge over LSAK on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 66% | +5.4 points |
| Q2 2026 | 66% | +17 points |
| Q1 2026 | 65% | +3.9 points |
| Q4 2025 | 63% | +0.8 points |
| Q3 2025 | 61% | -1.2 points |
| Q2 2025 | 49% | -16 points |
| Q1 2025 | 61% | -0.5 points |
| Q4 2024 | 62% | +4.9 points |
NVDA has the edge over LSAK on profitability, with a higher operating margin.
LSAK Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$15M | -404% |
| Q2 2026 | $7.5M | +$18.1M |
| Q1 2026 | $34.2M | +336% |
| Q4 2025 | -$14.8M | +$646K |
| Q3 2025 | $4.9M | +$13M |
| Q2 2025 | -$10.6M | -1229% |
| Q1 2025 | $7.8M | -52% |
| Q4 2024 | -$15.5M | -$13.9M |
LSAK's free cash flow has turned positive after six years mostly in the red: $12M over the past year.
NVDA Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $21.4B | +59% |
| Q2 2026 | $48.6B | +86% |
| Q1 2026 | $34.9B | +124% |
| Q4 2025 | $22.1B | +32% |
| Q3 2025 | $13.5B | -0.3% |
| Q2 2025 | $26.2B | +75% |
| Q1 2025 | $15.6B | +38% |
| Q3 2024 | $13.5B | +113% |
NVDA has the edge over LSAK on cash flow, with more consistent year-over-year improvement.
LSAK Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.2% | +198K shares |
| 1 year | +1.7% | +1.3M shares |
| 3 years | +39% | +22.5M shares |
LSAK has 80M diluted shares, up 1.7% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | $186,000 |
| Q2 2026 | $28,000 |
| Q1 2026 | $40,000 |
| Q4 2025 | $271,000 |
| Q2 2025 | $1M |
| Q1 2025 | $27,000 |
| Q4 2024 | $12.6M |
| Q2 2024 | $1.3M |
NVDA Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.4% | -106M shares |
| 1 year | -1% | -247M shares |
| 3 years | -2.8% | -705M shares |
| 5 years | -4.1% | -1B shares |
| Available history | -1.8% | -435M shares |
NVDA has the edge over LSAK on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $19.7B |
| Q2 2026 | $19.3B |
| Q1 2026 | $3.8B |
| Q4 2025 | $12.5B |
| Q3 2025 | $9.7B |
| Q2 2025 | $14.1B |
| Q1 2025 | $7.8B |
| Q4 2024 | $11B |
NVDA spent $55.3B buying back its own shares over the past year, up 30% from the year before.
LSAK Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 2.3x | Moderate |
| Q2 2026 | 2.2x | Moderate |
| Q1 2026 | 4.3x | High |
| Q4 2025 | 7.2x | High |
| Q3 2025 | 10.0x | High |
| Q2 2025 | 18.8x | High |
| Q1 2025 | 4.0x | High |
| Q4 2024 | 3.1x | Elevated |
LSAK's net debt is about 2.3 years of its operating earnings (EBITDA), down from 10 years a year ago.
NVDA Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 0.1x | Very low |
| Q2 2026 | -0.0x | Net Cash |
| Q1 2026 | -0.0x | Net Cash |
| Q4 2025 | -0.0x | Net Cash |
| Q3 2025 | -0.0x | Net Cash |
| Q2 2025 | -0.1x | Net Cash |
| Q1 2025 | -0.0x | Very low |
| Q4 2024 | -0.0x | Net Cash |
NVDA has the edge over LSAK on leverage, with a lower net debt burden relative to earnings.
LSAK Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 27.8 | Oversold |
| Stochastic | 5.2 | Oversold |
LSAK's weekly RSI is 28 (oversold) and its Stochastic is 5 (oversold).
NVDA Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 33.4 | Neutral |
| Stochastic | 18.1 | Oversold |
NVDA's weekly RSI is 33 (neutral) and its Stochastic is 18 (oversold).
LSAK PE vs Technology Sector
NVDA PE vs Technology Sector
| Metric | NVDA | Sector median | Relative |
|---|---|---|---|
| PE | 21x | 28x | 25% below |
| PE % | 0 | 35 | 35 pts below |
NVDA is trading at 21x earnings, a 25% discount to the Technology sector's median of 28x.
LSAK Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $4.07 | 18% below |
| 20 week MA | $4.40 | 25% below |
| 50 week MA | $4.58 | 28% below |
| 100 week MA | $4.56 | 27% below |
| 200 week MA | $4.39 | 24% below |
LSAK is in a downtrend: it's below all five of its weekly moving averages, and 24% below its 200-week average.
NVDA Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $208.9 | 20% below |
| 20 week MA | $212.0 | 22% below |
| 50 week MA | $199.9 | 17% below |
| 100 week MA | $175.1 | 5.1% below |
| 200 week MA | $123.6 | 34% above |
NVDA has the edge over LSAK on trend strength, trading above more of its moving averages.
LSAK Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $3.74 | $4.74 | +27% |
| 2021 | $4.74 | $5.41 | +14% |
| 2022 | $5.41 | $3.79 | -30% |
| 2023 | $3.79 | $3.24 | -15% |
| 2024 | $3.24 | $5.25 | +62% |
| 2025 | $5.25 | $4.36 | -17% |
| 2026 YTD | $4.36 | $3.32 | -24% |
LSAK has finished lower in three of the last six years. It's down 24% so far in 2026.
NVDA Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $5.92 | $13.0 | +119% |
| 2021 | $13.0 | $29.6 | +128% |
| 2022 | $29.6 | $15.2 | -49% |
| 2023 | $15.2 | $49.5 | +226% |
| 2024 | $49.5 | $137.0 | +177% |
| 2025 | $137.0 | $190.5 | +39% |
| 2026 YTD | $190.5 | $166.2 | -13% |
NVDA has the edge over LSAK on returns for 2026, with the stronger performance.